PT998271E - Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis - Google Patents

Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis

Info

Publication number
PT998271E
PT998271E PT98931204T PT98931204T PT998271E PT 998271 E PT998271 E PT 998271E PT 98931204 T PT98931204 T PT 98931204T PT 98931204 T PT98931204 T PT 98931204T PT 998271 E PT998271 E PT 998271E
Authority
PT
Portugal
Prior art keywords
drug
drugs
gastric
matrix
oral dosage
Prior art date
Application number
PT98931204T
Other languages
English (en)
Inventor
John W Shell
Jenny Louie-Helm
Original Assignee
Depomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25355537&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT998271(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Depomed Inc filed Critical Depomed Inc
Publication of PT998271E publication Critical patent/PT998271E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT98931204T 1997-06-06 1998-06-05 Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis PT998271E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87050997A 1997-06-06 1997-06-06

Publications (1)

Publication Number Publication Date
PT998271E true PT998271E (pt) 2005-10-31

Family

ID=25355537

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98931204T PT998271E (pt) 1997-06-06 1998-06-05 Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis

Country Status (11)

Country Link
US (2) US6340475B2 (pt)
EP (1) EP0998271B3 (pt)
JP (1) JP4083818B2 (pt)
AT (1) ATE302597T1 (pt)
AU (1) AU729529B2 (pt)
CA (1) CA2290624C (pt)
DE (1) DE69831335T3 (pt)
ES (1) ES2248908T7 (pt)
HK (1) HK1027298A1 (pt)
PT (1) PT998271E (pt)
WO (1) WO1998055107A1 (pt)

Families Citing this family (341)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CN1203846C (zh) 1998-03-19 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 高溶解性药物的双相控释递送***和方法
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP2003521507A (ja) 2000-02-04 2003-07-15 ディポメド，インコーポレイティド ゼロ次薬物放出に接近するシェル−コア剤形
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
JP2004509062A (ja) * 2000-02-29 2004-03-25 テバ　ファーマシューティカル　インダストリーズ　リミティド クラリスロマイシンおよびクラリスロマイシン中間体、本質的にオキシムを含まないクラリスロマイシン、およびそれを含んで成る医薬組成物を調製するための方法
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
ES2284709T3 (es) * 2000-09-29 2007-11-16 Solvay Pharmaceuticals B.V. Formulacion farmaceutica de liberacion sostenida independiente de la fuerza ionica.
DK1322158T3 (da) * 2000-10-02 2012-11-19 Usv Ltd Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
WO2002030392A2 (en) 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
KR100554816B1 (ko) * 2001-05-03 2006-02-22 에프. 호프만-라 로슈 아게 비결정질 넬피나비르 메실레이트의 약학 제형
CA2449009A1 (en) * 2001-05-29 2002-12-05 Depomed Development, Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
US6524618B1 (en) * 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
US20030021841A1 (en) * 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
CN1520286B (zh) * 2001-07-04 2010-12-01 太阳医药工业有限公司 胃滞留控制药物释出***
CN1268338C (zh) * 2001-07-06 2006-08-09 恩德制药公司 用作止痛剂的6－羟基羟***酮的口服给药
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
ATE376832T1 (de) * 2001-07-06 2007-11-15 Penwest Pharmaceuticals Co Verzögert freisetzende formulierungen von oxymorphon
ITMI20011457A1 (it) * 2001-07-09 2003-01-09 Valpharma Sa Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
WO2003026743A2 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US7413751B2 (en) 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
MXPA04004035A (es) * 2001-10-29 2004-10-29 Labopharm Inc Metodos y formas de dosis para mejorar la biodisponibilidad de agentes terapeuticos.
EA200400628A1 (ru) * 2001-11-06 2004-12-30 Рэнбакси Лабораториз Лимитед Таблетки метформина с контролируемым высвобождением активного компонента
US6667054B2 (en) * 2001-12-05 2003-12-23 Bernard Charles Sherman Metformin hydrochloride tablets
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
KR20050009983A (ko) * 2002-03-22 2005-01-26 시락 아게 트라마돌의 서방성 제제
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
WO2003099214A2 (en) * 2002-05-23 2003-12-04 Andrx Corporation Biguanide formulations
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
GB0214013D0 (en) * 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
US8679533B2 (en) * 2002-07-25 2014-03-25 Pharmacia Corporation Pramipexole once-daily dosage form
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
EP1549296A4 (en) * 2002-08-02 2006-08-09 Penwest Pharmaceuticals Co METFORMIN FORMULATIONS WITH DELAYED RELEASE
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
ATE448775T1 (de) * 2002-08-29 2009-12-15 Activbiotics Pharma Llc Rifalazil zur behandlung von infektionen mit clostridium difficile
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004032906A1 (en) * 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
EP1558081A4 (en) 2003-01-13 2006-06-14 Dynogen Pharmaceuticals Inc METHOD OF TREATING FUNCTIONAL INTESTINAL DISORDERS
EP1603540A2 (en) * 2003-03-14 2005-12-14 Nirmal Mulye A process for preparing sustained release tablets
JP2006522099A (ja) * 2003-04-04 2006-09-28 ファルマシア コーポレーション 複合粒状体からなる経口徐放性圧縮錠
EP2535042A1 (en) * 2003-06-16 2012-12-19 ANDRX Pharmaceuticals LLC. Oral sustained-release composition comprising a macrolide
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
EP1648418A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
EP1648415A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
US8313775B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20050238718A1 (en) * 2003-08-08 2005-10-27 Werner Oberegger Modified-release tablet of bupropion hydrochloride
EP1653925A1 (en) * 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
JP2007513869A (ja) * 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004289221B2 (en) * 2003-11-04 2009-12-17 Supernus Pharmaceuticals, Inc Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms
JP2007517039A (ja) * 2003-12-24 2007-06-28 アドバンシス ファーマスーティカル コーポレイション 変性放出製剤の吸収増強
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
KR100772980B1 (ko) * 2004-04-01 2007-11-02 한미약품 주식회사 메트포르민의 경구투여용 서방성 제제
EP1781261A1 (en) 2004-06-17 2007-05-09 Forest Laboratories, Inc. Modified release formulation of memantine
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CA2572292A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
EP2345407A1 (en) * 2004-08-13 2011-07-20 Boehringer Ingelheim International GmbH Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006015943A2 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006031856A2 (en) 2004-09-13 2006-03-23 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
AU2006242535B2 (en) * 2005-04-29 2012-08-09 Merck Sharp & Dohme Corp. Therapeutic compositions
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7544373B2 (en) 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US7541347B2 (en) 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
NZ561375A (en) * 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
US20070021379A1 (en) 2005-07-11 2007-01-25 Pharmena North America Inc. Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
WO2007020508A1 (en) * 2005-08-12 2007-02-22 Ferring International Center S.A. Method and device for dividing granules
NZ566642A (en) * 2005-08-30 2011-11-25 Piramal Life Sciences Ltd Extended release pharmaceutical composition of metformin and a process for producing it
US7569605B2 (en) 2005-10-14 2009-08-04 Forest Laboratories Holdings Limited Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
WO2007090881A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
EP2010158B1 (en) 2006-04-26 2016-02-17 Alphapharm Pty Ltd. Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
AU2013202441B2 (en) * 2006-04-26 2016-02-25 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
JPWO2008084698A1 (ja) 2006-12-28 2010-04-30 アステラス製薬株式会社 タクロリムス徐放性医薬組成物
WO2008093984A1 (en) 2007-01-29 2008-08-07 Hanall Pharmaceutical Company. Ltd N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
EP2139498B1 (en) 2007-03-22 2015-03-18 Dendreon Corporation Methods for detecting a natural killer (nk) cell-mediated immune response and an increase in nk cell activity
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
WO2009004592A1 (en) * 2007-07-03 2009-01-08 Wockhardt Research Centre Vancomycin compositions
CA2707980C (en) 2007-12-17 2015-05-12 Labopharm Inc. Misuse preventative, controlled release formulation
TWI454288B (zh) * 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
AU2009210641A1 (en) * 2008-02-05 2009-08-13 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
CN101959406A (zh) * 2008-03-04 2011-01-26 默沙东公司 二甲双胍和二肽基肽酶-ⅳ抑制剂的组合的药物组合物
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CA2720108C (en) * 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
JP5114281B2 (ja) * 2008-04-17 2013-01-09 塩野義製薬株式会社 塩酸バンコマイシンを含有する錠剤
EP2273983B1 (en) * 2008-05-09 2016-07-20 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
PL3692983T3 (pl) 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
ZA200903854B (en) 2008-06-19 2011-02-23 Univ Of The Witwatesrand Johannesburg A gastroretentive pharmaceutical dosage form
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
WO2010026467A2 (en) 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
BRPI0913724B8 (pt) 2008-09-18 2021-05-25 Purdue Pharma Lp formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
EP2346351B1 (en) 2008-09-22 2019-07-03 Rubicon Research Private Limited Compositions exhibiting delayed transit through the gastrointestinal tract
CN102307574A (zh) 2008-10-08 2012-01-04 鲍斯生命科学Pvt有限公司 缓释给药***
JP5667575B2 (ja) 2008-12-16 2015-02-12 パラディン ラブス インコーポレーテッド 誤用を防止する放出制御製剤
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
CN102481276A (zh) 2009-04-20 2012-05-30 埃尔舍利克斯治疗公司 基于化学感受受体配体的治疗法
CN102458557B (zh) 2009-05-05 2018-11-27 德州大学***董事会 挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
ES2560210T3 (es) 2009-07-22 2016-02-17 Grünenthal GmbH Forma de dosificación resistente a la manipulación para opiádes sensibles a la oxidación
US20110052700A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride
KR20120059582A (ko) * 2009-08-31 2012-06-08 데포메드 인코퍼레이티드 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물
US20110104273A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of phenylephrine
US20110135728A1 (en) * 2009-12-08 2011-06-09 Miller Jennifer L Gastric retentive pharmaceutical compositions for extended release of polypeptides
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2011095314A2 (en) * 2010-02-03 2011-08-11 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
JP2010120967A (ja) * 2010-02-24 2010-06-03 Shionogi & Co Ltd 塩酸バンコマイシンを含有する錠剤
PL2554168T3 (pl) 2010-03-29 2018-05-30 Astellas Pharma Inc. Kompozycja farmaceutyczna do kontrolowanego uwalniania
CN102858373B (zh) * 2010-03-31 2014-11-26 持田制药株式会社 易服用性固体制剂
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug
CA2807661C (en) 2010-08-11 2019-09-10 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
US9000046B2 (en) 2010-09-28 2015-04-07 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
MX2013004364A (es) 2010-10-19 2013-07-02 Elcelyx Therapeutics Inc Terapias a base de ligando del receptor quimiosensorial.
EP3400944B1 (en) 2010-11-08 2020-07-15 Albireo AB Ibat inhibitors for the treatment of liver diseases
WO2012078633A2 (en) 2010-12-07 2012-06-14 Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene Methods of inhibiting metastasis from cancer
CA2823397C (en) 2011-01-07 2020-03-10 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
CA2839126A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
DK2736495T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Misbrugsbestandig tablet som tilvejebringer øjeblikkelig frigivelse af lægemiddel
US9603805B2 (en) 2011-09-30 2017-03-28 Mochida Pharmaceutical Co., Ltd. Easily dosable solid preparation
TWI558401B (zh) 2011-11-01 2016-11-21 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
KR101939710B1 (ko) 2011-12-21 2019-01-17 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014015157A2 (en) 2012-07-19 2014-01-23 Philadelphia Health & Education Corporation Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
WO2014026013A2 (en) 2012-08-09 2014-02-13 Dynamis Therapeutics, Inc. Methods for maintaining or improving health, well-being and/or a physiological function in a subject
US20140150787A1 (en) * 2012-12-04 2014-06-05 Civitas Therapeutics, Inc. Devices and methods for puncturing a capsule to release a powdered medicament therefrom
EP2941233B1 (en) 2013-01-07 2020-10-07 The Trustees of the University of Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
WO2014167437A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
US20150366863A1 (en) 2013-03-28 2015-12-24 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014273226B2 (en) 2013-05-29 2019-06-27 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
JP2016520653A (ja) 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
PL3017054T3 (pl) 2013-07-02 2020-07-13 Ecoplanet Environmental Llc Preparaty lotnych związków organicznych o działaniu przeciwdrobnoustrojowym
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
JP6932506B2 (ja) 2013-11-26 2021-09-08 イエール ユニバーシティ 細胞透過組成物およびそれを用いる方法
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
EP3079692A4 (en) 2013-12-09 2017-10-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
US9982010B2 (en) 2014-04-07 2018-05-29 Women & Infants Hospital Of Rhode Island 7-dehydrocholesterol derivatives and methods using same
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
US20150359810A1 (en) 2014-06-17 2015-12-17 Celgene Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2015199146A1 (ja) * 2014-06-25 2015-12-30 味の素株式会社 固形製剤及びその安定化方法
US10709755B2 (en) 2014-06-25 2020-07-14 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
WO2016028753A1 (en) 2014-08-20 2016-02-25 Yale University Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
AU2015305449B2 (en) 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
EP3258916A1 (en) 2015-02-20 2017-12-27 Osmotica Kereskedelmi ES Szolgaltato KFT Controlled release oral dosage form of gaba receptor agonist with enhanced pharmacokinetics
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
CN107889459A (zh) 2015-04-24 2018-04-06 格吕伦塔尔有限公司 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
US10597368B2 (en) 2015-05-08 2020-03-24 Brown University Syringolin analogues and methods of making and using same
RU2757417C2 (ru) 2015-05-19 2021-10-15 Йейл Юниверсити Композиции для лечения патологических состояний кальцификации и способы их применения
WO2016201288A1 (en) 2015-06-12 2016-12-15 Brown University Novel antibacterial compounds and methods of making and using same
EP3316890B1 (en) 2015-06-30 2023-09-06 Neurad Ltd. Novel breathing control modulating compounds, and methods of making and using same
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
SG11201802964QA (en) 2015-10-15 2018-05-30 Celgene Corp Combination therapy for treating malignancies
US10905692B2 (en) 2015-10-15 2021-02-02 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
EA039829B1 (ru) 2015-10-15 2022-03-17 Аджиос Фармасьютикалз, Инк. Комбинированная терапия для лечения злокачественных опухолей
WO2017075145A1 (en) 2015-10-28 2017-05-04 Yale University Quinoline amides and methods of using same
WO2017087936A1 (en) 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same
CA3007363A1 (en) 2015-12-04 2017-06-08 Agios Pharmaceuticals, Inc. Methods of treatment of malignancies
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
AU2016393870B2 (en) 2016-02-26 2023-01-19 Celgene Corporation IDH1 inhibitors for the treatment of haematological malignancies and solid tumours
IL261756B2 (en) 2016-03-17 2023-11-01 Thiogenesis Therapeutics Inc Preparations for the controlled release of cysteamine and systemic treatment of disorders sensitive to cysteamine
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US10292977B2 (en) 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US10143687B2 (en) 2016-04-11 2018-12-04 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US20180064817A1 (en) * 2016-04-23 2018-03-08 Jayendrakumar Dasharathlal Patel Tamper Resistant Pharmaceutical Composition
US20190119364A1 (en) 2016-04-29 2019-04-25 The Regents Of The University Of Colorado, A Body Corporate Compounds and compositions useful for treating metabolic syndrome, and methods using same
WO2018026764A1 (en) 2016-08-01 2018-02-08 University Of Rochester Nanoparticles for controlled release of anti-biofilm agents and methods of use
US20180042930A1 (en) 2016-08-03 2018-02-15 Celgene Corporation Methods of treatment of malignancies
EP3493829B1 (en) 2016-08-05 2024-04-17 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
CA3035205A1 (en) 2016-09-01 2018-03-08 Mebias Discovery Llc Substituted ureas and methods of making and using same
JP7113009B2 (ja) 2016-11-07 2022-08-04 アービュタス バイオファーマ コーポレイション 置換ピリジノン含有三環式化合物およびそれを使用する方法
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US10941126B2 (en) 2017-01-19 2021-03-09 Temple University-Of The Commonwealth System Of Higher Education Bridged bicycloalkyl-substituted aminothiazoles and their methods of use
WO2018172852A1 (en) 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
US11166953B2 (en) 2017-04-17 2021-11-09 Yale University Compounds, compositions and methods of treating or preventing acute lung injury
EP3618828B1 (en) 2017-05-05 2023-11-01 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
CN110996922A (zh) 2017-06-16 2020-04-10 卡希夫生物科学有限责任公司 用于持续药物递送的胃滞留剂型
WO2019018158A1 (en) 2017-07-17 2019-01-24 Eli Lilly And Company PHARMACEUTICAL COMPOSITIONS
US11376223B2 (en) 2017-07-17 2022-07-05 Eli Lilly And Company Pharmaceutical compositions
US20210085796A1 (en) 2017-07-28 2021-03-25 Yale University Anticancer drugs and methods of making and using same
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
AU2018330171A1 (en) 2017-09-08 2020-03-12 The Regents Of The University Of Colorado, A Body Corporate Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers
CA3076392A1 (en) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
AU2018360383A1 (en) 2017-11-02 2020-05-21 Natureceuticals Sdn. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
CN111818929A (zh) 2017-11-27 2020-10-23 由卫生与公众服务部部长代表的***合众国 用于治疗和/或预防牙周疾病的化合物、组合物和方法
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
JP2021506984A (ja) 2017-12-18 2021-02-22 トリス・フアルマ・インコーポレーテツド トリガーパルス薬物放出を有する胃内滞留型ｒａｆｔ形成システムを含む放出調節薬物粉末組成物
EP3737353A1 (en) 2017-12-18 2020-11-18 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
EP3743060A4 (en) 2018-01-24 2021-11-03 The Rockefeller University ANTIBACTERIAL COMPOUNDS, RELATED COMPOSITIONS AND THEIR METHODS OF USE
US11337963B2 (en) 2018-01-29 2022-05-24 Duke University Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
KR20210015892A (ko) 2018-05-29 2021-02-10 세르시 테라퓨틱스 인코포레이티드 통증 치료를 위한 화합물, 이를 포함하는 조성물 및 이를 사용하는 방법
CA3100113A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP3609472B1 (en) 2018-06-18 2020-12-30 Kashiv Specialty Pharmaceuticals, LLC Extended release compositions comprising pyridostigmine
WO2019245925A1 (en) 2018-06-19 2019-12-26 National University Of Singapore Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
KR20210024033A (ko) 2018-06-20 2021-03-04 알비레오 에이비 오데빅시바트의 약학 제제
TWI826492B (zh) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
KR102651652B1 (ko) 2018-10-11 2024-03-26 사니핏 테라퓨틱스 에스.에이. 이소성 석회화의 치료를 위한 이노시톨 포스페이트
WO2020092915A1 (en) * 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
US20210403452A1 (en) 2018-11-02 2021-12-30 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
JP2022521119A (ja) 2019-01-30 2022-04-06 サニフィット・セラピューティクス・ソシエダッド・アノニマ 組織の灌流の増加における使用のためのイノシトールリン酸化合物
WO2020159588A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
WO2020159565A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
KR102186704B1 (ko) * 2019-02-18 2020-12-04 (주)아이엠디팜 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물
WO2020227603A1 (en) 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Hmgb1 antagonist
EP3983391A4 (en) 2019-06-12 2023-06-28 The Wistar Institute Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
FI4069360T3 (fi) 2019-12-04 2024-02-20 Albireo Ab Bentsotia(di)atsepiinin yhdisteet ja niiden käyttö sappihapon modulaattoreina
ES2973355T3 (es) 2019-12-04 2024-06-19 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
EP4069359B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
BR112022024958A2 (pt) 2020-06-09 2022-12-27 Inozyme Pharma Inc Proteínas enpp1 solúveis e usos das mesmas
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
AU2022320730A1 (en) 2021-07-30 2024-03-14 Evecxia Therapeutics, Inc. 5-hydroxytryptophan gastroretentive dosage forms
WO2023064598A1 (en) 2021-10-14 2023-04-20 Evecxia Therapeutics, Inc. A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
WO2024023360A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip5 substituted compounds
WO2024023359A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863981A (en) * 1986-06-30 1989-09-05 Ciba-Geigy Corporation Synergistic mixture of stabilizers
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
EP0830129B1 (fr) * 1995-04-14 2002-03-20 Pharma Pass Compositions solides contenant du polyethyleneoxyde et un principe actif non amorphe
EP0761209A3 (en) * 1995-09-01 1998-02-04 J.B. Chemicals & Pharmaceuticals Ltd. Controlled release formulations of ranitidine
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs

Also Published As

Publication number Publication date
AU729529B2 (en) 2001-02-01
EP0998271A1 (en) 2000-05-10
EP0998271B1 (en) 2005-08-24
ATE302597T1 (de) 2005-09-15
JP2000513028A (ja) 2000-10-03
CA2290624C (en) 2006-12-05
ES2248908T7 (es) 2014-11-24
WO1998055107A1 (en) 1998-12-10
HK1027298A1 (en) 2001-01-12
DE69831335T2 (de) 2006-06-08
EP0998271B3 (en) 2014-10-29
US20010018070A1 (en) 2001-08-30
US20020051820A1 (en) 2002-05-02
ES2248908T3 (es) 2006-03-16
DE69831335T3 (de) 2015-01-15
JP4083818B2 (ja) 2008-04-30
US6340475B2 (en) 2002-01-22
AU8138698A (en) 1998-12-21
DE69831335D1 (de) 2005-09-29
CA2290624A1 (en) 1998-12-10

Similar Documents

Publication Publication Date Title
PT998271E (pt) Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
CA2364845A1 (en) Extending the duration of drug release within the stomach during the fed mode
Debotton et al. Applications of polymers as pharmaceutical excipients in solid oral dosage forms
US4900755A (en) Controlled release combination of carbidopa/levodopa
US4832957A (en) Controlled release combination of carbidopa/levodopa
KR101946037B1 (ko) 투여 제형
Bodmeier Tableting of coated pellets
AU597670B2 (en) Controlled release combination of carbidopa/levodopa
CN1022666C (zh) 固体药物剂型的制备
Lenaerts et al. Controlled release of theophylline from cross-linked amylose tablets
JP5400377B2 (ja) 圧縮性に乏しい治療用化合物を有する組成物の製造法
US4983400A (en) Controlled release combination of carbidopa/levodopa
JP5635082B2 (ja) 剤形
AU570712B2 (en) Crosslinked, porous polymers for controlled drug delivery
EP0250374B1 (en) Therapeutic system for controlled release of drugs
CA2014451A1 (en) Sustained-release oral drug dosage form
EP0139127A1 (en) Transdermal drug delivery device and its preparation
WO2010041279A3 (en) Sustained release drug delivery system
US4428926A (en) Sustained release propranolol system
US4851231A (en) System for delivering drug in selected environment of use
Tiwari et al. Oral drug delivery system: a review
Shah et al. Review on sustained release matrix tablets: An approach to prolong the release of drug
US20070148227A1 (en) Physically/molecularly distributed and/or chemically bound medicaments in capsule shells
WO1998003161A1 (en) Controlled release tablets
Kumari et al. Formulation and Evaluation of Gastro Retentive Matrix Tablets of Sitagliptin